Avenue Therapeutics Inc ATXI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATXI is a good fit for your portfolio.
News
-
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
-
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
-
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
-
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
-
Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study
-
Avenue Therapeutics Shares Jump 30% on FDA Meeting Minutes
Trading Information
- Previous Close Price
- $0.13
- Day Range
- $0.13–0.14
- 52-Week Range
- $0.11–1.25
- Bid/Ask
- $0.12 / $0.14
- Market Cap
- $5.75 Mil
- Volume/Avg
- 323,345 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- 0.03
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.avenuetx.com
Valuation
|
Metric
|
ATXI
|
|---|---|
Price/Earnings (Normalized) | 0.03 |
Price/Book Value | 2.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ATXI
Financial Strength
|
Metric
|
ATXI
|
|---|---|
Quick Ratio | 1.49 |
Current Ratio | 1.55 |
Interest Coverage | −30.97 |
Quick Ratio
ATXI
Profitability
|
Metric
|
ATXI
|
|---|---|
Return on Assets (Normalized) | −358.36% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −742.27% |
Return on Assets
ATXI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fsbgbmnry | Wfbr | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nftplhjc | Xkwkdw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vskpghkqd | Wwkxsrw | $98.1 Bil | |
MRNA
| Moderna Inc | Mqhqvbjc | Mtbqm | $39.1 Bil | |
ARGX
| argenx SE ADR | Jvlkxkd | Hqftr | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Jrxlhbbb | Shzfy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jzcbzflly | Gytltss | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pdqmnlsw | Qdlywq | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Chzmybjkgm | Zncgp | $12.5 Bil | |
INCY
| Incyte Corp | Rxfdttxg | Rdfthc | $11.9 Bil |